Valuation: Tonix Pharmaceuticals Holding Corp.

Market Cap 211M 185M 170M 159M 299M 19.88B 305M 2.05B 792M 9.82B 791M 774M 34.07B P/E 2026 *
-1.29x
P/E 2027 * -2.13x
Enterprise Value 211M 185M 170M 159M 299M 19.88B 305M 2.05B 792M 9.82B 791M 774M 34.07B EV / Sales 2026 *
6.16x
EV / Sales 2027 * 2.67x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-28 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI
05-11 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Tonix Pharmaceuticals Holding Corp. Secures Commercial Payer Coverage for TONMYA CI
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
05-04 TD Cowen Initiates Coverage on Tonix Pharmaceuticals With Buy Rating, $22 Price Target MT
04-29 Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800 CI
03-31 Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease CI
03-26 Tonix Pharmaceuticals Doses First Participant in Potential Migraine Treatment Study MT
03-26 Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 CI

Last Transcript: Tonix Pharmaceuticals Holding Corp.

1 day+10.35%
1 week+10.07%
Current month+7.22%
1 month+8.81%
3 months+2.64%
6 months-18.70%
Current year-15.36%
1 week 11.58
Extreme 11.585
13.57
1 month 10.03
Extreme 10.03
13.57
Current year 10.03
Extreme 10.03
19.95
1 year 10.03
Extreme 10.03
69.97
3 years 6.76
Extreme 6.76
6,016
5 years 6.76
Extreme 6.76
774,400
10 years 6.76
Extreme 6.76
1,000,000
Manager TitleAgeSince
Chief Executive Officer 68 2007-11-15
Director of Finance/CFO 52 2016-01-31
Chief Tech/Sci/R&D Officer 57 2025-02-03
Director TitleAgeSince
Director/Board Member 78 2018-02-12
Director/Board Member 66 2020-06-08
Director/Board Member 81 2018-09-04
Date Insider Type Main position Quantity % Market Cap.
06-11Buy

Director

1,415 0.0120%
06-08Buy

Chief Executive Officer

5,000 0.0425%
06-07Buy

Director

5,000 0.0425%
Change 5-day change 1-year change 3-year change Capi.($)
+10.35%+10.07%-62.11%-99.71% 211M
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +3.42%+8.21%+21.68%+39.12% 361.63B
Weighted average by Cap. +3.85%+8.93%+41.75%+80.16%

Financials

2026 *2027 *
Net sales 34.18M 29.97M 27.63M 25.87M 48.5M 3.22B 49.51M 332M 128M 1.59B 128M 126M 5.53B 78.93M 69.21M 63.8M 59.73M 112M 7.45B 114M 767M 297M 3.68B 296M 290M 12.76B
Net income -170M -149M -137M -129M -241M -16.03B -246M -1.65B -639M -7.92B -638M -624M -27.48B -152M -133M -123M -115M -215M -14.32B -220M -1.47B -571M -7.08B -570M -558M -24.55B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
26-06-26 US$13.22 +10.35% 1,608,875
26-06-25 US$11.98 -0.99% 718,144
26-06-24 US$12.10 +1.17% 401,159
26-06-23 US$11.96 -1.97% 466,920
26-06-22 US$12.20 +1.58% 396,549
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.22USD
Average target price
42.20USD
Spread / Average Target
+219.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNXP Stock